Richard Greene, MD
Urology · Olympia, WANPI 1568610707
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.0%), education and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Intuitive Surgical at 36.3% of the total. Reporting peaked in 2022 at $6,123 and has fallen 71.3% since, to $1,755 in 2025.
Across 135 payments — averaging $90.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Teleflex LLC$3K
- Procept Biorobotics Corporation$1K
- Coloplast$828
- Astellas Pharma US Inc$310
- Sumitomo Pharma America, Inc.$277
- plus $2K from 26 others
What the payments were for
- Travel & lodging$2,12717%
- Food & beverage$5,98649%
- Education$4,10034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $4,428 |
| Teleflex LLC | 19 | $2,607 |
| Procept Biorobotics Corporation | 10 | $1,317 |
| Coloplast | 13 | $828 |
| Astellas Pharma US Inc | 10 | $310 |
| Sumitomo Pharma America, Inc. | 7 | $277 |
| Progenics Pharmaceuticals, Inc. | 7 | $274 |
| Myriad Genetic Laboratories, Inc. | 9 | $242 |
| Dornier Medtech America, Inc | 1 | $174 |
| Olympus America Inc. | 2 | $161 |
| 180 Medical, Inc. | 3 | $147 |
| Johnson & Johnson(2 entities) | 4 | $142 |
| Boston Scientific | 4 | $134 |
| AbbVie | 4 | $116 |
| Convatec Inc. | 3 | $113 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $110 |
| Merck | 5 | $103 |
| Neotract Inc. | 2 | $99 |
| Valencia Technologies Corporation | 1 | $92 |
| Urogen Pharma, Inc. | 3 | $89 |
| Verity Pharmaceuticals Inc. | 4 | $78 |
| Tolmar, Inc. | 3 | $68 |
| Calyxo, Inc. | 3 | $64 |
| Pfizer | 2 | $41 |
| AstraZeneca | 1 | $35 |
| Laborie Medical Technologies Corp. | 1 | $34 |
| Cook Medical LLC | 2 | $31 |
| Endo USA, Inc. | 1 | $27 |
| Accord Healthcare, Inc. | 1 | $23 |
| ABC Home Medical Supply, Inc. | 1 | $20 |
| Axonics, Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,266
- UroLift$1,775
- AquaBeam Robotic System$1,058
- UroLift System$673
- TITAN$276
- Dornier MedTech$174
- iTIND System$131
- GEMTESA$130
- Prolaris$125
- PYLARIFY$109
How this compares
$12,213 in reported general payments places this provider in the 85th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 34 | $30,122 |
| Tamsulosin Hcl | 177 | $3,141 |
| Solifenacin Succinate | 53 | $2,344 |
| Estradiol | 19 | $1,850 |
| Ondansetron OdtOndansetron | 73 | $1,263 |
| Finasteride | 92 | $1,225 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 28 | $863 |
| Oxybutynin Chloride | 81 | $847 |
| Testosterone Cypionate | 16 | $445 |
| Cefdinir | 21 | $377 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 76 | $364 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 73 | $353 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $276 |
| Levofloxacin | 63 | $176 |
| Oxycodone Hcl | 11 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $310 | $30,12234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 274 urology providers in Washington.
Other urology in Olympia
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Raymond LanceSpokane$211K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Kevin OstrowskiKirkland$64K
- Marco SalazarEdmonds$58K
- Anthony BuiVancouver$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.